1. Introduction {#sec1-antioxidants-09-00760}
===============

In the early 1980s, 'big K' channel (BK~Ca~), named after its large single-channel conductance 250--300 pS (in symmetrical 150 mM KCl), was originally cloned in *Drosophila* at the slowpoke (slo) \[[@B1-antioxidants-09-00760],[@B2-antioxidants-09-00760]\]. In mammals, BK~Ca~ channels were defined as large-conductance calcium-activated potassium ion channels (BK~Ca~, MaxiK, K~Ca~1.1, Slo1) and were characterized in bovine chromaffin cells, rabbit skeletal muscle, and rat muscle cells \[[@B1-antioxidants-09-00760],[@B2-antioxidants-09-00760],[@B3-antioxidants-09-00760]\]. BK~Ca~ channels are ubiquitously expressed in a broad range of excitable and inexcitable cell types \[[@B4-antioxidants-09-00760]\], as well as in intracellular organelles, including mitochondria \[[@B5-antioxidants-09-00760]\], nuclei \[[@B6-antioxidants-09-00760]\], endoplasmic reticulum \[[@B7-antioxidants-09-00760],[@B8-antioxidants-09-00760]\], and lysosomes \[[@B2-antioxidants-09-00760],[@B9-antioxidants-09-00760],[@B10-antioxidants-09-00760]\], where they are termed as iBK~Ca~ \[[@B10-antioxidants-09-00760]\]. BK~Ca~ channels participate in a wide variety of fundamental physiological processes from vascular tone \[[@B11-antioxidants-09-00760],[@B12-antioxidants-09-00760]\], cardiac rhythmicity \[[@B11-antioxidants-09-00760],[@B13-antioxidants-09-00760]\], erectile and urinary autonomic functions \[[@B14-antioxidants-09-00760],[@B15-antioxidants-09-00760]\], regulation of gene expression \[[@B6-antioxidants-09-00760]\], and aging \[[@B16-antioxidants-09-00760]\]. Recent reports suggest that alterations of BK~Ca~ function and expression may associate with several pathological conditions, such as paroxysmal nonkinesigenic dyskinesia with a gain of function, and cerebellar ataxia with loss-of-function mutations \[[@B17-antioxidants-09-00760],[@B18-antioxidants-09-00760]\], making them unique therapeutic targets. The exclusive initiative by the '*KCNMA1 channelopathy international advocacy foundation*' has brought BK~Ca~-associated disorders to the forefront and facilitates education, treatment, and networking opportunities for KCNMA1 channelopathy patients, physicians, and researchers \[[@B19-antioxidants-09-00760]\].

The activity of BK~Ca~ channels is regulated by two physiological stimuli: Membrane depolarization and intracellular calcium levels, and either calcium or voltage can independently modulate its function \[[@B20-antioxidants-09-00760],[@B21-antioxidants-09-00760]\]. Under normal physiological conditions, both factors simultaneously modulate BK~Ca~-mediated ion currents, but in the absence of calcium, membrane depolarization alone can elicit BK~Ca~ currents. On the other hand, calcium binding decreases the energy required to open the channel and causes a shift of open probability (P~O~) towards more negative voltages \[[@B21-antioxidants-09-00760],[@B22-antioxidants-09-00760]\]. *Kcnma1* gene codes for α-subunit that assembles into a pore-forming tetramer, a primary BK~Ca~ channel functional unit \[[@B23-antioxidants-09-00760]\]. α-subunit consists of the transmembrane region (S0-S6) and large intracellular C-terminus \[[@B23-antioxidants-09-00760]\]. S1-S4 transmembrane segments create the voltage-sensing domain, whereas S5-S6 form the channel pore. The C-terminus contains ligand-binding motifs, phosphorylation sites, and a stretch of negatively charged amino acids that form 'Ca^2+^ bowls' \[[@B24-antioxidants-09-00760]\]. In addition to pore-forming, α-subunit tetramer can co-assemble with auxiliary subunits, β (β1- β4) and γ (γ1- γ4) \[[@B24-antioxidants-09-00760],[@B25-antioxidants-09-00760],[@B26-antioxidants-09-00760],[@B27-antioxidants-09-00760]\]. The channel pore can co-assemble with zero to four regulatory subunits, and the number and kind of regulatory subunits present can significantly alter channel performance as well as its activity \[[@B27-antioxidants-09-00760]\]. BK~Ca~ channels with different subunit combinations can present a wide range of channel activity, rates of activation or deactivation, current rectification properties, and sensitivity to pharmacological agents \[[@B27-antioxidants-09-00760]\]. When taking into consideration the number of splice variants and a plethora of combinations in which BK~Ca~ channels can assemble, one can understand the functional diversity that is uniquely calibrated for the needs of a variety of cells in which they are expressed \[[@B4-antioxidants-09-00760],[@B5-antioxidants-09-00760],[@B10-antioxidants-09-00760],[@B17-antioxidants-09-00760]\].

Though BK~Ca~ channels are uniformly present in all cell types, they have recently been brought into the forefront in cardiovascular studies \[[@B4-antioxidants-09-00760],[@B10-antioxidants-09-00760],[@B28-antioxidants-09-00760],[@B29-antioxidants-09-00760],[@B30-antioxidants-09-00760],[@B31-antioxidants-09-00760],[@B32-antioxidants-09-00760],[@B33-antioxidants-09-00760],[@B34-antioxidants-09-00760]\]. They have been implicated in several pathophysiological conditions and cardiovascular diseases \[[@B2-antioxidants-09-00760],[@B5-antioxidants-09-00760],[@B35-antioxidants-09-00760],[@B36-antioxidants-09-00760],[@B37-antioxidants-09-00760],[@B38-antioxidants-09-00760],[@B39-antioxidants-09-00760],[@B40-antioxidants-09-00760],[@B41-antioxidants-09-00760],[@B42-antioxidants-09-00760],[@B43-antioxidants-09-00760],[@B44-antioxidants-09-00760],[@B45-antioxidants-09-00760],[@B46-antioxidants-09-00760],[@B47-antioxidants-09-00760],[@B48-antioxidants-09-00760],[@B49-antioxidants-09-00760],[@B50-antioxidants-09-00760],[@B51-antioxidants-09-00760]\]. In this review, we exclusively focus on the functions of BK~Ca~ channels in the cardiac system and their role in protection from acute myocardial infarction (AMI).

2. Localization of BK~Ca~ Channels {#sec2-antioxidants-09-00760}
==================================

BK~Ca~ channels are heterogeneously expressed in the cardiovascular system. BK~Ca~ channels are present in the plasma membrane of vascular smooth muscle, where they contribute to the regulation of resting membrane potential \[[@B52-antioxidants-09-00760],[@B53-antioxidants-09-00760]\] and play a critical role in myogenic tone regulation \[[@B48-antioxidants-09-00760],[@B49-antioxidants-09-00760],[@B54-antioxidants-09-00760]\]. BK~Ca~ channel activity provides hyperpolarizing currents that facilitate negative feedback to vasoconstriction induced by high intravascular pressure \[[@B48-antioxidants-09-00760]\]. BK~Ca~-dependent vasoregulation in smooth muscles is attributed to the coupling of α subunits with its regulatory β1 subunit \[[@B48-antioxidants-09-00760]\]. This configuration of the channel increases its Ca^2+^ sensitivity, changes gating energetics, and current kinetics, therefore, shifts its open probability towards more negative voltages than those determined for channels formed by α subunits alone \[[@B25-antioxidants-09-00760],[@B48-antioxidants-09-00760],[@B55-antioxidants-09-00760]\]. Furthermore, β1 knockout mice showed decreased BK~Ca~ calcium sensitivity, which leads to increased arterial tone and blood pressure \[[@B48-antioxidants-09-00760],[@B56-antioxidants-09-00760]\].

BK~Ca~ also plays an active role in heart rate regulation. In 2010, the first evidence was presented for the presence of BK~Ca~ channels in the heart and its involvement in the regulation of heart rate \[[@B57-antioxidants-09-00760]\]. Heart rate is determined by the sinoatrial node (SAN), which is a primary pacemaker of the cardiac conduction system \[[@B58-antioxidants-09-00760]\]. Electrophysiological characterization of isolated SAN cells showed a 55 ± 15% reduction in action potential (AP) firing when paxilline (BK~Ca~ specific inhibitor) was applied \[[@B11-antioxidants-09-00760]\]. Moreover, SAN cells isolated from *Kcnma1^-/-^* mice showed a 33% lower baseline firing rates when compared to wild type \[[@B11-antioxidants-09-00760]\]. These findings indicate the presence of BK~Ca~ channels in the plasma membrane of SAN cells. BK~Ca~ in SAN are shown to be functionally coupled with L-type calcium channel Ca~v~1.3, which are expressed in sinoatrial and atrioventricular nodes but not in ventricular cardiomyocytes, and are responsible for pacemaker currents \[[@B59-antioxidants-09-00760]\]. Both channels are located at the plasma membrane within the "Ca^2+^ nanodomain" region, and influx through Ca~v~1.3 guarantees a local Ca^2+^ increase sufficient enough for BK~Ca~ activation at physiological voltages \[[@B60-antioxidants-09-00760]\].

BK~Ca~ channels have not been detected in the plasma membrane of adult cardiomyocytes; on the other hand, comprehensive electrophysiological, biochemical, and pharmacological data indicated the presence of BK~Ca~ channels in the inner mitochondrial membrane (IMM) of cardiomyocytes ([Figure 1](#antioxidants-09-00760-f001){ref-type="fig"}) \[[@B5-antioxidants-09-00760],[@B38-antioxidants-09-00760],[@B43-antioxidants-09-00760]\]. Mitochondrial BK~Ca~ (mitoBK~Ca~) is a product of the *Kcnma1* gene, the same gene that encodes the α subunit of the plasma membrane BK~Ca~ channel, but in cardiomyocytes, a specific DEC splice variant determines protein mitochondrial localization \[[@B5-antioxidants-09-00760]\]. mitoBK~Ca~ channel activity increases K^+^ conductance and improves mitochondria respiratory function by reducing the production of reactive oxygen species (ROS) and decreasing deleterious intra-mitochondrial Ca^2+^ accumulation, which plays a major role in heart protection against ischemia/reperfusion (I/R) injury \[[@B5-antioxidants-09-00760],[@B34-antioxidants-09-00760],[@B46-antioxidants-09-00760],[@B61-antioxidants-09-00760],[@B62-antioxidants-09-00760]\]. Surprisingly, BK~Ca~ channel currents were measured on the cell membrane of ventricular myocytes isolated from chick embryos \[[@B63-antioxidants-09-00760],[@B64-antioxidants-09-00760],[@B65-antioxidants-09-00760],[@B66-antioxidants-09-00760]\]. Currents measured in chick embryonic ventricular myocytes showed all the hallmark characteristics of BK~Ca~ channels, including iberiotoxin sensitivity and "big" single-channel conductance of approximately 270 pS \[[@B64-antioxidants-09-00760],[@B66-antioxidants-09-00760]\]. The absence of BK~Ca~ channels in the cell membrane of adult cardiomyocytes but the presence in embryonic cardiomyocytes strongly suggests that during development, BK~Ca~ channels undergo a change of the expressed splicing variant that determines mitochondrial but not plasma membrane localization. Further investigations will be needed to probe the expression pattern of the BK~Ca~ channel during cardiac developmental stages.

Fibroblasts constitute a significant fraction of the heart and they are key determinants of both the structure and function of the myocardium \[[@B67-antioxidants-09-00760]\]. Functional expression of BK~Ca~ channels was identified in cultured human cardiac fibroblasts \[[@B68-antioxidants-09-00760],[@B69-antioxidants-09-00760],[@B70-antioxidants-09-00760],[@B71-antioxidants-09-00760]\]. Potassium currents were sensitive to highly selective BK~Ca~ inhibitors, paxilline, and iberiotoxin and demonstrated 162 ± 8 pS single-channel conductance \[[@B69-antioxidants-09-00760]\]. Cardiac fibroblasts play a central role in the maintenance of the extracellular matrix in normal hearts and act as mediators of inflammatory and fibrotic myocardial remodeling in the injured heart. It is also becoming increasingly clear that cardiac fibroblasts contribute to the electrophysiological remodeling mediated by BK~Ca~ channels \[[@B69-antioxidants-09-00760]\]. One of the mathematical simulations predicts that BK~Ca~ channels activity in cardiac fibroblasts may contribute to the alteration in myocardial action potential when tight electrical coupling forms between those two types of cells \[[@B69-antioxidants-09-00760]\]. Furthermore, fibroblasts may act as a current "sink" and prevent impulse propagation that leads to the development of cardiac arrhythmias, but the role of BK~Ca~ in this process needs further evaluation to decipher the precise role and mechanism involved \[[@B72-antioxidants-09-00760]\].

3. Role of BK~Ca~ Channel Agonists {#sec3-antioxidants-09-00760}
==================================

The ubiquitous BK~Ca~ expression, a dual activation mechanism that allows them to couple intracellular signaling to membrane potential and significantly modulate physiological responses in a plethora of tissues, prompted intense development of BK~Ca~ channel modulators \[[@B73-antioxidants-09-00760],[@B74-antioxidants-09-00760]\]. The number of identified molecules is significant and growing, which is why we will limit this review to regularly used pharmacological tools ([Figure 2](#antioxidants-09-00760-f002){ref-type="fig"}) to study BK~Ca~.

Among the first synthetic BK~Ca~ activators were benzimidazoles NS004 \[[@B75-antioxidants-09-00760]\] and NS1619 \[[@B76-antioxidants-09-00760]\] ([Figure 2](#antioxidants-09-00760-f002){ref-type="fig"}) and the latter became one of the most used agonists in establishing the physiological functions of BK~Ca~. NS1619 accelerated K^+^ mitochondrial uptake, improving mitochondrial respiratory function, but its link to cardioprotection was made when NS1619 was administered prior to the ischemic event and protected isolated perfused rat hearts from global I/R injury \[[@B38-antioxidants-09-00760]\]. Subsequent studies confirmed that the administration of NS1619 protected the heart from I/R injury in mice \[[@B77-antioxidants-09-00760],[@B78-antioxidants-09-00760]\], rats \[[@B79-antioxidants-09-00760],[@B80-antioxidants-09-00760]\], guinea pigs \[[@B41-antioxidants-09-00760]\], rabbits \[[@B43-antioxidants-09-00760]\], and dogs \[[@B81-antioxidants-09-00760]\]. To further elucidate cardioprotective mechanisms, several studies probed ROS production and mitochondrial Ca^2+^ levels during ischemia and reperfusion. Isolated guinea pig hearts were subjected to I/R injury in the presence and absence of NS1619 \[[@B41-antioxidants-09-00760]\]. Hearts were nearly continuously monitored for levels of nicotinamide adenine dinucleotide (NAD) + hydrogen (H) (NADH), superoxide, and mitochondrial calcium and NS1619 showed attenuated levels when compared with untreated hearts that resulted in an astounding 50% decrease in infarct size \[[@B41-antioxidants-09-00760]\]. Those effects were nullified by paxilline and superoxide dismutase, showing that both BK~Ca~ channel activity and superoxide are necessary for the cardioprotective effect \[[@B41-antioxidants-09-00760]\]. However, an increased number of investigations showed poor potency and inadequate selectivity of NS1619. At higher concentrations, NS1619 (at \~100 µM) inhibits L-type Ca^2+^ channels in rat ventricular cardiomyocytes \[[@B82-antioxidants-09-00760]\], Ca^2+^-activated chloride channels \[[@B83-antioxidants-09-00760]\], and voltage-activated Ca^2+^, K^+^, and Na^+^ channels \[[@B76-antioxidants-09-00760],[@B84-antioxidants-09-00760],[@B85-antioxidants-09-00760]\]. Additionally, few studies determined non-ion channel effects of NS1619 on functions of other proteins like endoplasmic reticulum Ca^2+^-ATPase and complex I, ATP-synthase, which raised questions about the role of BK~Ca~ channels in cardioprotection \[[@B86-antioxidants-09-00760],[@B87-antioxidants-09-00760]\]. Our group clarified pharmacological controversy by showing cardioprotective effects of NS1619 (up to 30 µM) in wild-type mice that were not observed in *Kcnma1^-/-^* animals, additionally showing that pretreatment with NS1619 increases the mitochondrial Ca^2+^ retention capacity in wild-type but not in *Kcnma1^-/-^* animals \[[@B5-antioxidants-09-00760]\]. Because of the limited usefulness of NS1619, the need for a specific and sensitive activator led to the development of NS11021. NS11021 displayed better specificity and potency (10 times higher than NS1619) and activation of BK~Ca~ by parallel shifting the channel activation curves to more negative potentials \[[@B88-antioxidants-09-00760]\]. The single-channel analysis revealed that NS11021 increased the open probability by altering the gating kinetics without altering the single-channel conductance \[[@B88-antioxidants-09-00760]\]. It also did not influence the number of cloned K~V~ channels or endogenous Na^+^ and Ca^2+^ channels in cardiomyocytes isolated from guinea pigs \[[@B88-antioxidants-09-00760]\]. In nanomolar concentrations, NS11021 displayed beneficial effects on mitochondria by accelerating the initial K^+^ uptake by 2.5 fold, an increase in mitochondrial volume with very little effect on membrane potential, which translates into an increase in the mitochondrial respiratory response \[[@B61-antioxidants-09-00760]\]. Studies have also shown an improvement of mitochondrial energy production via oxidative phosphorylation, leading to increased ATP sustainability, and allowing cardiomyocytes to tolerate greater oxygen deprivation \[[@B42-antioxidants-09-00760],[@B61-antioxidants-09-00760]\]. This leads to reduced mitochondrial Ca^2+^, delayed opening of mitochondrial permeability transition pore (mPTP), postponement of apoptosis initiation, and ultimately, mitoBK~Ca~ channel activity prolongs the survival of cardiomyocyte during ischemic insult \[[@B41-antioxidants-09-00760],[@B89-antioxidants-09-00760]\].

In addition to previously mentioned synthetic activators, a plethora of endogenous modulators have been studied that induce similar changes in BK~Ca.~ These molecules include gasotransmitters, such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H~2~S) \[[@B90-antioxidants-09-00760]\]. CO has been shown to increase the open probability (P~O~) of BK~Ca~ by mimicking the action of Ca^2+^ because the mutation of residues responsible for Ca^2+^ sensitivity also prevented channel CO sensitivity \[[@B91-antioxidants-09-00760],[@B92-antioxidants-09-00760]\]. Furthermore, the same mechanism appears to be responsible for BK~Ca~ activation by H^+^, which could contribute to BK~Ca~'s cardioprotective function, as intracellular pH falls by 0.5 to 1 unit during the early stages of ischemia and changes in extracellular acidosis had no significant effect on BK~Ca~ \[[@B92-antioxidants-09-00760],[@B93-antioxidants-09-00760],[@B94-antioxidants-09-00760],[@B95-antioxidants-09-00760],[@B96-antioxidants-09-00760]\]. NO is a well-established vasodilatory factor released by endothelial cells and it has been shown to significantly increase P~O~ of BK~Ca~ by direct interactions and/or through cyclic guanosine monophosphate (cGMP)-mediated phosphorylation \[[@B97-antioxidants-09-00760],[@B98-antioxidants-09-00760]\]. Another molecule from the gasotransmitter group is H~2~S, a biologically active gas that plays a role in the physiology and pathophysiology of cardiovascular and nervous systems \[[@B99-antioxidants-09-00760],[@B100-antioxidants-09-00760]\]. There are conflicting data showing contradictory results that vary from inhibition of native and recombinant currents of the α subunit expressed in human embryonic kidney (HEK)-293 cells \[[@B101-antioxidants-09-00760]\], through to β1 subunit presence and enhanced oxidative regulation and BK~Ca~ activation \[[@B102-antioxidants-09-00760]\], to the BK~Ca~ response dependent on channel priming by PKG phosphorylation \[[@B103-antioxidants-09-00760]\]. These findings indicate the complexity of BK~Ca~ signaling, which heavily depends on allosteric interactions, oxidative state, phosphorylation, divalent ion concentration, and voltage. MitoBK~Ca~, because of their localization, are continuously exposed to ROS. It has been reported that H~2~O~2~ increased the survival of cardiomyocytes that underwent I/R simulation \[[@B104-antioxidants-09-00760]\]. However, BK~Ca~ regulation by ROS depends on oxidative species, which can activate, inhibit, or leave the channel unaltered \[[@B90-antioxidants-09-00760],[@B105-antioxidants-09-00760]\]. Data suggest that superoxide anion (O~2~^−^) has little effects on BK~Ca~ function, peroxynitrite (ONOO^−^) decreases activity, and H~2~O~2~ action depends on the tissue type and experimental conditions and it may have both an excitatory and inhibitory effect \[[@B90-antioxidants-09-00760],[@B105-antioxidants-09-00760]\].

4. Role of BK~Ca~ Channel Antagonists {#sec4-antioxidants-09-00760}
=====================================

Antagonists and inhibitors ([Figure 2](#antioxidants-09-00760-f002){ref-type="fig"}) of BK~Ca~ channels are widely used for cardioprotection studies. One of the most widely used small molecules and synthetically derived BK~Ca~ channel blockers is tetraethylammonium chloride (TEA) \[[@B106-antioxidants-09-00760],[@B107-antioxidants-09-00760]\]. TEA blocks channel activity by binding within the ion conduction pathway in a voltage-dependent manner from both sides of the membrane; however, it lacks selectivity for BK~Ca~ channels as TEA blocks several voltage-gated potassium channels \[[@B108-antioxidants-09-00760],[@B109-antioxidants-09-00760]\]. Venom from scorpions is an invaluable source of BK~Ca~ inhibitors. The first potent BK~Ca~ blocker was a 37-amino-acid peptide charybdotoxin (ChTX) identified in 1985 \[[@B110-antioxidants-09-00760]\]; however, because of its inhibitory effect on K~v~1.3 and intermediate-conductance Ca^2+^-activated-K^+^ channels (IK channels), currently, ChTX use in BK~Ca~-specific studies is limited \[[@B111-antioxidants-09-00760]\]. Another 37-aa peptide isolated from scorpion venom was iberiotoxin (IbTX), which showed high selectivity and affinity for BK~Ca~ channels \[[@B112-antioxidants-09-00760]\]. The blocking mechanism of ChTX and IbTX is attributed to their binding to the external pore region of the channel through bimolecular reaction and physically blocking the conduction pathway \[[@B113-antioxidants-09-00760]\]. Toxins, because of their peptide properties, such as rapid degradation, poor reversibility, and blood-brain barrier, are less than ideal for extended research use or drug development.

The next group of non-peptide BK~Ca~ channel inhibitors is a family of tremorgenic mycotoxins isolated from fungi and this group includes potent neurotoxin paxilline (PAX) \[[@B114-antioxidants-09-00760]\]. Paxilline is the non-peptide neurotoxin most extensively used in research because of its high selectivity and reversibility of action, and capability of a 70% BK~Ca~ channel current inhibition at a concentration as low as 10 nM (K~i~ = 1.9 nM), and its site of action is located on the α-subunit and cytoplasmic side \[[@B115-antioxidants-09-00760],[@B116-antioxidants-09-00760]\]. IbTX and PAX were used in multiple studies to determine the role of BK~Ca~ channels in the cardiovascular system. PAX resulted in a significant decrease (30%) in the heart rate of wild-type mice with no effect on mean blood pressure \[[@B57-antioxidants-09-00760]\]. This effect was transient and concentration-dependent. To remove the possibility of systematic effects of PAX, isolated and perfused rat hearts also showed a decreased heart rate due to PAX (34%) and IbTX (60%) treatment \[[@B57-antioxidants-09-00760]\]. IbTX is not cell permeable and those results suggested that BK~Ca~ channels expressed on the cell membrane of SAN cells play a role in heart rate regulation, not channels presented on IMM as we have seen in adult cardiomyocytes. Those findings were reproduced with a similar heart rate reduction caused by PAX, further supporting the presence of BK~Ca~ on the plasma membrane of SAN cells \[[@B11-antioxidants-09-00760]\]. However, a recently published study conducted a rapid assessment of cardiac function after intravenous injection of PAX and IbTX \[[@B34-antioxidants-09-00760]\]. On the one hand, PAX did produce significant bradycardia as reported \[[@B11-antioxidants-09-00760],[@B57-antioxidants-09-00760]\], while, on the other hand, IbTX treatment showed no changes and PAX effects were reversible within 15 min after injection \[[@B34-antioxidants-09-00760]\]. The contrasting findings (in vivo vs. ex vivo) with IbTX demonstrate the need for further investigation to determine the localization and biophysical properties of BK~Ca~ channels in SAN cells that are responsible for heart rate regulation. An in vivo implanted telemetry EKG monitoring system that allowed continuous monitoring in awake unrestrained mice after intraperitoneal injection of PAX showed a significant heart rate reduction, prolongation of the P-P interval, without prolongation of the P-R interval \[[@B11-antioxidants-09-00760]\]. Those findings indicate that the mechanism involves SAN cells' firing rate (spontaneous depolarization), with AV node conduction unaffected \[[@B11-antioxidants-09-00760]\]. To exclude the autonomous effects of PAX, perforated patch-clamp recordings of isolated SAN cells were perfused with PAX, and seven out of eight cells showed a significant reduction of the firing rate consistent with in vivo findings \[[@B11-antioxidants-09-00760]\]. Action potential (AP) waveform analysis showed a slowing of the diastolic depolarization without changes in the depolarization duration fitting, with the telemetric findings in vivo \[[@B11-antioxidants-09-00760]\]. Like in the case of the activators, endogenous molecules play the role of BK~Ca~ channel blockers. Heme is a fundamentally important molecule and evidence suggests that free intracellular heme acts as a non-genomic signaling molecule that can acutely modulate BK~Ca~ channels \[[@B117-antioxidants-09-00760],[@B118-antioxidants-09-00760]\]. Heme regulatory actions have been examined under a variety of physiological conditions, showing that it modifies the voltage-dependent gating by shifting the G-V curve towards more depolarizing voltages \[[@B119-antioxidants-09-00760],[@B120-antioxidants-09-00760]\]. This regulation remained similar at saturating levels of divalent cations, showing that heme disrupts both Ca^2+^ and voltage-dependent gating, resulting in decreasing ionic currents. However, at more hyperpolarized and potentially more physiological voltages, heme actually enhanced channel activity \[[@B99-antioxidants-09-00760],[@B119-antioxidants-09-00760]\]. Furthermore, CO reversed BK~Ca~ channel inhibition by heme, but not hemin (oxidized heme), and on BK~Ca~ binding, CO heme switches from being a channel inhibitor to an activator, making heme a functional CO receptor for the BK~Ca~ channels \[[@B121-antioxidants-09-00760]\].

BK~Ca~ blockers were used in combination with activators to farther validate BK~Ca~ channels' involvement in the area of interest that especially applies to I/R injury research. As we previously mentioned, BK~Ca~ was localized in IMM of cardiomyocytes, and treatment with NS1619 (BK~Ca~ opener) protected the heart during I/R injury, reflected in the significantly reduced infarct size \[[@B38-antioxidants-09-00760]\]. This effect was reversed by PAX, which allowed the identification of BK~Ca~ channels as a major player in cardioprotection, and since then, those finding have been confirmed in numerous animal models \[[@B38-antioxidants-09-00760],[@B41-antioxidants-09-00760],[@B43-antioxidants-09-00760],[@B77-antioxidants-09-00760],[@B78-antioxidants-09-00760],[@B79-antioxidants-09-00760],[@B80-antioxidants-09-00760],[@B81-antioxidants-09-00760],[@B122-antioxidants-09-00760],[@B123-antioxidants-09-00760]\]. For clarification of the mechanism by which BK~Ca~ channels resulted in a cardioprotective effect, close monitoring of mitochondrial changes during I/R injury was required. Continuous monitoring of NADH, superoxide, and mitochondrial Ca^2+^ levels in guinea pig hearts subjected to I/R injury revealed a significant reduction in mitochondrial Ca^2+^ capacity, ROS production, and levels of NADH on treatment with NS1619, which affected the end result: Infarct size was reduced by more than 50% in comparison to the control group \[[@B41-antioxidants-09-00760]\]. Those cardioprotective effects were negated by PAX and superoxide dismutase, which indicated that both BK~Ca~ channels and superoxide activity are necessary to elicit cytoprotective effects \[[@B41-antioxidants-09-00760]\]. At present, the proposed mechanism of cytoprotection starts with preconditioning, which leads to a mild increase of superoxide levels, which trigger the activation of BK~Ca~ channels. K^+^ influx into mitochondria partially depolarizes IMM and reduces Ca^2+^ influx during I/R injury, preventing mitochondrial Ca^2+^ overload, mPTP opening, and apoptosis initiation \[[@B41-antioxidants-09-00760]\]. This proposed mechanism is being evaluated in genetic animal models, which we will review in the next section.

5. Genetic Animal Models {#sec5-antioxidants-09-00760}
========================

To further evaluate the role of BK~Ca~ channels in cardiac physiology and pathophysiology, several genetic mouse models were developed. The first reported *Kcnma1^-/-^* (*Kcnma1* global knockout) mice colony showed approximately normal Mendelian birth ratios of 28.5% for *Kcnma1^+/+^*, 50% for *Kcnma1^+/-^*, and 21.5% for *Kcnma1^-/-^* (296 mice) \[[@B124-antioxidants-09-00760]\]. Similar to Slopoke flies \[[@B16-antioxidants-09-00760]\], *Kcnma1^-/-^* animals were 27% smaller at 2 weeks than their littermates, but by week 5, null-mutant mice achieved a similar body weight \[[@B124-antioxidants-09-00760]\]. *Kcnma1^-/-^* mice showed moderate ataxia and deficits in motor performance \[[@B124-antioxidants-09-00760]\]. *Kcnma1^-/-^* were able to produce offspring, but the success rate was significantly reduced as only 1 out of 20 *Kcnma1^-/-^* males crossed with wild-type females was able to sire a normal-sized litter \[[@B124-antioxidants-09-00760]\]. Additionally, 40% of *Kcnma1^-/-^* mice on the inbred FVB/NJ background died at 2.2 ± 0.3 months from unknown causes \[[@B124-antioxidants-09-00760]\]. The use of *Kcnma1^-/-^* mice allowed researchers to further evaluate the specificity and side effects of BK~Ca~ channel agonists and blockers. BK~Ca~ channel blockers, Loritrem B, and PAX had no effects on heart rate and blood pressure in *Kcnma1^-/-^* mice, while administration of those inhibitors in conscious wild-type littermates caused a 30% and 42% reduction in heart rate, respectively \[[@B57-antioxidants-09-00760]\]. This finding suggests that bradycardia was specifically mediated by α-subunit activity. Interestingly, the baseline heart rate did not vary between *Kcnma1^-/-^* and wild-type animals \[[@B57-antioxidants-09-00760]\]. Lai et al. reported a similar basal heart rate in *Kcnma1^-/-^* and wild-type groups, confirming previous findings \[[@B11-antioxidants-09-00760]\]. Analysis of the electrocardiogram (EKG) intervals in *Kcnma1^-/-^* mice showed no difference in P-P and R-R intervals when compared to wild-type mice \[[@B11-antioxidants-09-00760]\]. Cells isolated from SAN of *Kcnma1^-/-^* mice showed slower basal firing rates and prolongation of the diastolic depolarization, mimicking the characteristics of wild-type SAN cells treated with PAX \[[@B11-antioxidants-09-00760]\]. Those findings suggested that the unchanged basal heart rate in vivo is likely to be the extrinsic compensatory mechanism or *Kcnma1^-/-^* SAN cells compensate from the membrane potential and achieve homeostasis, while wild-type cells are unable to do so with acute inhibition of BK~Ca~ \[[@B11-antioxidants-09-00760]\]. We determined mitoBK~Ca~ as a splice variant that requires the expression of the DEC exonic sequence at the c-terminus to target the inner mitochondrial membrane \[[@B5-antioxidants-09-00760]\]. In the same study, NS1619-preconditioning cardioprotective effects were negated in *Kcnma1^-/-^* mice \[[@B5-antioxidants-09-00760]\]. Soltysinska et al. used transmission electron microscopy to evaluate ventricular cardiomyocytes isolated from *Kcnma1^-/-^* mice and did not detect any abnormalities in the mitochondria structure and matrix dimensions \[[@B42-antioxidants-09-00760]\]. In *Drosophila*, mitochondria in flight muscles showed cristae disintegration and swelling \[[@B16-antioxidants-09-00760]\]. Surprisingly, oxidative phosphorylation capacities at normoxia and upon re-oxygenation after anoxia were significantly reduced in *Kcnma1^-/-^* cardiomyocytes \[[@B42-antioxidants-09-00760]\] but not in flies during aging in the absence of BK~Ca~ channels \[[@B16-antioxidants-09-00760]\]. Wild-type and *Kcnma1^-/-^* underwent ex vivo I/R injury with or without ischemic preconditioning \[[@B42-antioxidants-09-00760]\]. Wild-type hearts showed a significant reduction in infarct size 28±3% (of the area at risk) when compared with *Kcnma1^-/-^* hearts 58 ± 5% (of the area at risk), with these findings suggesting that the BK~Ca~ channel mediates the cardioprotective benefits of ischemic preconditioning and supporting the conclusion from several other studies that the implicated BK~Ca~ channels in the respiratory chain and its disruption influence the infarct size \[[@B5-antioxidants-09-00760],[@B38-antioxidants-09-00760],[@B42-antioxidants-09-00760],[@B50-antioxidants-09-00760]\].

The conditional mutant lacking the endogenous *Kcnma1* exclusively from cardiomyocytes (*CM-Kcnma1-Cre^fl/fl^*) brought a new level of specificity to the research of cardioprotective mechanisms by removing systemic effects that had to be taken under consideration in *Kcnma1^-/-^* global knockout. *CM-Kcnma1-Cre^fl/fl^* mice did not develop an obvious phenotype, exhibiting a normal body and heart weight; however, echocardiography showed a mild reduction in the cardiac ejection fraction, fraction shortening, heart rate, and significantly lower arterial blood pressure \[[@B47-antioxidants-09-00760]\]. Animals were also subjected to an open-chest model of myocardial infarction and cardiac damage was compared between wild-type, *Kcnma1^-/-^* (global knockout), *CM-Kcnma1-Cre^fl/fl,^*, and *SM-Kcnma1-Cre^fl/fl^* (conditional mutant lacking *Kcnma1* from smooth muscle) \[[@B47-antioxidants-09-00760]\]. Infarct size was significantly larger in *Kcnma1^-/-^* and *CM-Kcnma1-Cre^fl/f^* when compared with wild-type animals, revealing that the cardiomyocyte-specific BK~Ca~ channel accounts for \>50% of the cardioprotection \[[@B47-antioxidants-09-00760]\]. Infarct size in *SM-Kcnma1-Cre^fl/fl^* was similar to the wild-type group, showing that BK~Ca~ channels in vascular smooth muscle were not involved in pathological events elicited by I/R injury \[[@B47-antioxidants-09-00760]\]. Furthermore, histological results were confirmed with serum cardiac troponin I levels, where larger infarct corresponded with higher troponin serum levels \[[@B47-antioxidants-09-00760]\]. The administration of PAX resulted in a significant increase in heart damage in wild-type mice but had no effects on *CM-Kcnma1-Cre^fl/fl^* animals \[[@B47-antioxidants-09-00760]\]. Interestingly, NS11021 treatment reduced infarct size in both wild-type and *CM-Kcnma1-Cre^fl/fl^*, although the effects were much smaller in knockout animals, which again brings back a question about NS11021 specificity that we discussed in the agonist section \[[@B47-antioxidants-09-00760]\]. This study also tested the hypothesis that cardiomyocyte BK~Ca~ channels function within the cGMP/cGKI pathway with the use of guanylate cyclase activators (riociguat and cinaciguat). In wild-type mice, I/R with the administration of agents significantly reduced infarct size (42.5% riociguat, and 50.5% for cinaciguat) \[[@B47-antioxidants-09-00760]\]. This cardioprotection was strongly attenuated in the case of riociguat and completely abolished in the case of cinaciguat and these results confirm that cGMP/cGKI pathway signaling contributes to cardiomyocyte protection during I/R injury \[[@B47-antioxidants-09-00760]\]. This mechanism depends on BK~Ca~ channel activity, which agrees with previous studies where BK~Ca~ channels were directly stimulated by cGMP/cGKI \[[@B125-antioxidants-09-00760],[@B126-antioxidants-09-00760],[@B127-antioxidants-09-00760]\]. These data indicate that mitoBK~Ca~ is possibly preset downstream of the cGMP pathway. To evaluate long-term changes, wild-type and *CM-Kcnma1-Cre^fl/fl^* were followed for 4 weeks post I/R injury. There was no difference in the survival rate, heart weight, or ventricular function as both groups showed similar results; however, levels of fibrosis were significantly increased in the *CM-Kcnma1-Cre^fl/fl^* group \[[@B47-antioxidants-09-00760]\]. These studies present strong evidence that the cardioprotective effect depends on BK~Ca~ channel activity in cardiomyocytes, where BK~Ca~ is present in inner mitochondrial membranes.

Pharmacological activation implicated cardiomyocyte BK~Ca~ in cardioprotection; however, the usage of agonists remains controversial due to their non-specific effects. This limitation was addressed by using a genetic model that expressed a *Kcnma1*^R207Q^ constitutively active BK~Ca~ channel mutant (Tg-BK~Ca~^R207Q^) \[[@B46-antioxidants-09-00760]\]. Tg-BK~Ca~^R207Q^ did not present any adverse cardiovascular phenotype, as the cardiac function parameters measured by echocardiography indicated no differences between wild-type and Tg-BK~Ca~^R207Q^ animals in the left ventricular ejection fraction, fraction shortening, and aortic velocity \[[@B46-antioxidants-09-00760]\]. Hearts from wild-type and Tg-BK~Ca~^R207Q^ were subjects of I/R injury, with or without ischemic preconditioning. Results showed that in both models, with or without ischemic preconditioning, infarct size was significantly smaller in the Tg-BK~Ca~^R207Q^ group, showing that Tg-BK~Ca~^R207Q^ was better protected from I/R injury than the wild type \[[@B46-antioxidants-09-00760]\]. Since ROS production is implicated in cardioprotection, ROS was measured in the heart-isolated mitochondria of Tg-BK~Ca~^R207Q^ mice. Genetic activation of BK~Ca~ channels reduced ROS after I/R stress and preconditioning further decreased it \[[@B46-antioxidants-09-00760]\], directly implicating BK~Ca~ channels in the modulation of mitochondrial ROS generation. Those results showed that activation of the BK~Ca~ channel is essential for cardiac recovery from I/R injury and is a factor in ischemic preconditioning-mediated cardioprotection.

6. BK~Ca~ as a Therapeutic Target for Cardioprotection {#sec6-antioxidants-09-00760}
======================================================

Data from 2017 show that 48% (121.5 million) of adults in the US suffer from cardiovascular disease and it is a leading cause of death (30.5% of deaths in 2017 in the US) \[[@B128-antioxidants-09-00760]\]. Coronary heart disease, including AMI, was attributed to 42.6% of cardiovascular disease-related deaths, followed by stroke (17.0%) and high blood pressure (10.5%) \[[@B128-antioxidants-09-00760]\]. AMI in addition to acute damage can develop into heart failure, which is another major factor in cardiovascular mortality \[[@B128-antioxidants-09-00760]\]. Cardiomyocyte death during AMI develops in two stages, ischemic injury and reperfusion injury, which contributes up to 50% of infarct size, but clinically, reopening the occluded vessel is the best AMI treatment available at this moment \[[@B129-antioxidants-09-00760]\]. Infarct size is a determinant of myocardial functional recovery and therapies aimed at the reduction of reperfusion injuries are highly desired.

The first preconditioning intervention was reported in 1986 when it was demonstrated that four short ischemic-reperfusion pulses resulted in a dramatic 75% decrease in infarct size \[[@B130-antioxidants-09-00760]\]. The nature of this protective mechanism suggested the involvement of the K^+^ channel. The role of BK~Ca~ channels in cardiomyocytes was neglected because of their absence from the plasma membrane of cardiomyocytes \[[@B10-antioxidants-09-00760]\]. However, in 2002, O'Rourke's group reported voltage- and calcium-dependent potassium currents on mitoplasts isolated from guinea pig cardiomyocytes \[[@B38-antioxidants-09-00760]\]. The recorded currents had a single-channel conductance of \~307 pS and were blocked by ChTX \[[@B38-antioxidants-09-00760]\]. Furthermore, NS1619 protected the heart from the ischemic event and this effect was blocked by PAX \[[@B38-antioxidants-09-00760]\]. Subsequent studies confirmed that NS1619 protected the heart from I/R injury in a number of animal species and administration of NS11021, before or right after, also protected the heart from I/R injury \[[@B50-antioxidants-09-00760],[@B131-antioxidants-09-00760]\]. Because most of the data addressing the role of mitoBK~Ca~ channels in cardioprotection relied on pharmacological tools, the data published were questioned because both activators and blockers displayed unspecific effects. Our group resolved controversies about pharmacology, showing that the cardioprotection offered by NS1619 was lost in *Kcnma1^-/-^* mice and clearly demonstrating BK~Ca~ channels' involvement in cardioprotection, which was also confirmed with the use of cardiomyocyte-specific knockouts, *CM-Kcnma1-Cre^fl/fl^* \[[@B5-antioxidants-09-00760],[@B47-antioxidants-09-00760]\]. Additionally, changes in ROS production and attenuated oxidative phosphorylation in *Kcnma1^-/-^* cardiomyocytes were also observed, suggesting the role of mitoBK~Ca~ in fine-tuning the oxidative state of the cell \[[@B42-antioxidants-09-00760]\]. We still do not have a clear picture of how the BK~Ca~ channel contributes to cardioprotection, although a few mechanisms have been proposed. The BK~Ca~ channel affects mitochondrial Ca^2+^ accumulation, K^+^ influx leads to partial depolarization if the IMM reduces the driving force for Ca^2+^ entry, and prevents Ca^2+^ overload during I/R injury \[[@B41-antioxidants-09-00760],[@B44-antioxidants-09-00760]\]. Additionally, pre-treatment with NS1619 increased mitochondria Ca^2+^ retention capacity, an effect that was lost in *Kcnma1^-/-^* mice \[[@B5-antioxidants-09-00760]\].

The role of mitoBK~Ca~ has also been shown in the regulation of ROS production in various models. Isolated mitochondria from cardiomyocytes and neurons showed decreased ROS production when stimulated with NS1619, which was confirmed in isolated hearts and a *Kcnma1^-/-^* mice model, where mitochondria isolated from knockout mice showed elevated ROS production after the anoxic event \[[@B41-antioxidants-09-00760],[@B42-antioxidants-09-00760],[@B131-antioxidants-09-00760]\]. Moreover, mitoBK~Ca~ opening has been shown to improve mitochondrial energy production by swelling of the mitochondrial matrix \[[@B61-antioxidants-09-00760]\]. An attenuated phosphorylation capacity was also identified in a *CM-Kcnma1-Cre^fl/fl^* mice model, which further connected mitoBK~Ca~ activity with ATP preservation \[[@B42-antioxidants-09-00760]\]. During reperfusion, after an ischemic event, mitoBK~Ca~ activity would improve oxidative phosphorylation, decrease ROS production, and improve mitochondria Ca^2+^ retention, preventing opening of the mitochondrial permeability transition pore (mPTP), which would lead to mitochondria collapse, termination of ATP synthesis, and cardiomyocyte death \[[@B40-antioxidants-09-00760]\]. The recent findings with the use of pharmacological tools and genetic models have clearly demonstrated that BK~Ca~ channels are important for cardioprotection, regulation of vascular tone, and mitochondrial function. However, there are still variations in results that seem to depend on the methods chosen and experimental design, and imperfect activators and blockers that display a number of unspecific side effects. The number of synthetic BK~Ca~ activators have been developed through the years by different pharmaceutical companies, with promising results in animal models, but with limited success in clinical trials \[[@B131-antioxidants-09-00760]\]. The research established mitoBK~Ca~ channels as a promising target for limiting reperfusion damage and correcting long-term events that occur after AMI, but further research will be needed to develop clinical pharmacological tools for cardiac disease in the future.

7. Conclusions and Future Directions {#sec7-antioxidants-09-00760}
====================================

Over the past 30 years, BK~Ca~ has been cloned and characterized in several pathological and physiological conditions. The establishment of the KCNMA1-channelopathy consortium has truly pushed BK~Ca~ as a therapeutic target for several neuronal and other possible diseases. In the heart, several animal models have shown that activation of BK~Ca~ channels, either pharmacologically or genetically, protects the heart from ischemia-reperfusion injury. In humans, the *Kcnma1* gene is positioned within the first locus mapped from familial atrial fibrillation on chr10q23. Genetic-linkage analysis indicated that the gene responsible for atrial fibrillation (AF) is located on chromosome 10q in the region of 10q22--q24 \[[@B36-antioxidants-09-00760]\]. The original candidate genes thought to be involved in AF were β-adrenergic receptor (ADRB1)13 and α-adrenergic receptor (ADRA2)14 located on 10q23--q26, and G-protein-coupled receptor kinase (GPRK5) 15, which interacts with adrenergic receptors. Sequence analysis of these candidate genes failed to identify any pathogenic variants. The chromosome 10q22-q24 AF locus also overlaps with loci mapped with other cardiac disorders, such as arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and hypoplastic left heart syndrome. *Kcnma1* has largely been ignored from screens as it was originally reported to be absent in cardiomyocytes \[[@B35-antioxidants-09-00760]\]. Given the recent studies focused on establishing their molecular identity, its roles in the regulation of heart rate, and its roles of cardiomyocyte BK~Ca~ channels in cardioprotection, and its location in Chr10q23, it is a very promising candidate gene for cardiac pathophysiology.
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![BK~Ca~ signaling in cardiomyocytes mitochondria during ischemia-reperfusion (I/R) injury. I/R injury causes an increase of reactive oxygen species (ROS) production and Ca^2+^ overload that leads to mPTP opening, the collapse of membrane potential (ΔΨ~IMM~), and the release of cytochrome C that causes cell death. The opening of BK~Ca~ protects the heart by reducing ROS and increasing the calcium retention capacity, hence delaying the opening of mPTP. IMM---Inner mitochondria membrane, OMM---Outer mitochondria membrane. mitoBK~Ca~ activators (NS1619, NS11021), mitoBK~Ca~ inhibitors (PAX-paxilline, IbTX-iberiotoxin), mPTP-mitochondrial permeability transition pore.](antioxidants-09-00760-g001){#antioxidants-09-00760-f001}
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